Activation of FXR Suppresses Esophageal Squamous Cell Carcinoma Through Antagonizing ERK1/2 Signaling Pathway

Abstract

These findings identify that activating FXR may serve as a promising therapy or adjuvant therapeutic tool for controlling ESCC development.